RSS

Prokarium

UK-based synthetic biology company, Prokarium, has completed an investment round, raising $10 million for the clinical development of vaccines against chlamydia, C.difficile and enteric fever, plus an expansion for the immune-oncology R&D team more

News

EPM sat down with Ted Fjällman, CEO of Prokarium, a company tasked with developing vaccines against bioterrorist threats, to find out more about this growing danger. more

News